| Trial ID: | L6742 |
| Source ID: | NCT02608905
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Effect of Dapagliflozin on Inflammation and Endothelial Function
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02608905/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Monocyte Inflammatory Protein Nuclear Factor Kappa-B (NFkappaB) (%), The percentage change in monocyte inflammatory proteins NFkappaB (%) from baseline in patients with type 2 diabetes., 12 weeks | Secondary: Arterial Flow Mediated Dilatation (%), The percentage change in arterial flow mediated dilation (%) from baseline as measured by ultrasound in patients with type 2 diabetes., 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Baylor College of Medicine
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
17
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2015-11
|
| Completion Date: |
2019-03
|
| Results First Posted: |
2020-04-08
|
| Last Update Posted: |
2020-04-08
|
| Locations: |
Baylor College of Medicine, Houston, Texas, 77030, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02608905
|
